Nevertheless, the administration of AMPK activators has been shown to substantially boost both AMPK and PGC-1α activity, leading to improvements in symptoms such as blood glucose levels, lipid profiles, and insulin resistance (Wang et al., 2010; Hardie, 2013). The gene discussed is PPARGC1A; the disease is Insulin resistance.